Tricog Health is a Bengaluru-based Indian healthtech company that combines AI with in-house cardiologists to read ECGs and other cardiac tests remotely for hospitals and clinics.

This Startup Deep Dive explains what Tricog does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Tricog in Brief

• What it is: Tricog is an Indian Healthtech, cardiac AI company based in Bengaluru.
• Who it serves: businesses, institutions, consumers, learners and public-sector buyers.
• Provides an AI and telemedicine platform for cardiac diagnosis and management, with cardiologists verifying AI readings and returning certified reports.
• Products include InstaECG, InstaEcho, VCardia and KeeboHealth.
• Platform is deployed in over 5,000 cath labs, hospitals, clinics and diagnostic centres, per a 2023 report.
• Funding: About $30 million per company statement in 2023 (aggregators range from about $21 million to $32.5 million).

Tricog Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Tricog?

Tricog operates in the Healthtech, cardiac AI space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Tricog.

• Provides an AI and telemedicine platform for cardiac diagnosis and management, with cardiologists verifying AI readings and returning certified reports.
• Products include InstaECG, InstaEcho, VCardia and KeeboHealth.
• Platform is deployed in over 5,000 cath labs, hospitals, clinics and diagnostic centres, per a 2023 report.
• Adding home-based remote patient monitoring with OMRON devices.

The Origin Story of Tricog

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Charit Bhograj, Zainul Charbiwala, Udayan Dasgupta.
• Began with real-time ECG analysis and expanded into a broader cardiac telemedicine suite.
• Founding year reports differ: 2014 in aggregator profiles, 2015 in a 2023 news report.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Healthtech, cardiac AI sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2018: Series A round (per funding coverage).
• March 2020: $10.5 million Series B led by UTEC, bringing total funding to $17.5 million.
• April 2023: $8.5 million Series B2 from OMRON Healthcare and Sony Innovation Fund with UTEC, Inventus Partners and SG Innovate.
• FY25: Aggregator lists revenue of Rs 77.7 crore (figure appears unreliable, see numbers).

Tricog Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• March 2020: $10.5 million Series B, led by UTEC; Aflac Ventures, TeamFund and Dream Incubator joined, with Inventus Capital and Blume Ventures participating.
• April 2023: $8.5 million Series B2; new investors OMRON Healthcare and Sony Innovation Fund; existing investors UTEC, Inventus Partners and SG Innovate.

How Does Tricog Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to businesses, institutions, consumers, learners and public-sector buyers, sales cycles and contract size matter as much as headline growth.

• B2B, largely pay-per-use: hospitals and clinics pay per ECG or echo read, keeping cost low for small providers.
• Also hardware sales and subscription software, per a data profile.
• Combines AI with a team of in-house cardiologists.

The Numbers: Tricog Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY25: revenue Rs 77.7 crore, net loss Rs 1.3 crore (aggregator figure).
• FY24: revenue Rs 9.0 crore per the same aggregator; the jump looks implausible, so reports differ and should be treated with caution.

Market Opportunity for Tricog

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising digital adoption, cloud and mobile penetration, growing enterprise technology spending, government digitisation programmes and a deep pool of engineering talent. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Expansion focus on Asia and Africa and a larger US footprint.
• Targets underserved cardiac care via remote reads and home monitoring.

Technology and Product at Tricog

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are product quality, data and integration depth, security, scalability and the speed of shipping improvements.

• AI for ECG and echo analysis with human cardiologist review.
• Cloud platform connecting devices to cardiologists.

Team and Culture at Tricog

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Charit Bhograj is CEO.
• Zainul Charbiwala is chief technology officer.
• Udayan Dasgupta is chief data scientist (per a profile).

Tricog Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Tricog

• Revenue figures are inconsistent across data sources.
• Competition from global cardiac AI firms.
• Regulatory requirements in new markets.
• Reliance on cardiologist capacity.
• Competition: low barriers to entry and well-funded rivals can compress pricing and slow growth.
• Funding risk: technology businesses often burn cash before reaching profit and depend on investor appetite.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by data protection rules under the Digital Personal Data Protection Act, sector regulators, consumer protection law and IT rules.

Tricog Growth Outlook: What to Watch

• Plans to scale remote patient monitoring across Asia and Africa.
• Partnerships with OMRON and Sony point to a consumer and home-health push.
• Key indicators: recurring revenue, customer retention, gross margin, customer acquisition cost and runway.
• Funding position: Whether Tricog can reach its next milestone before needing new capital.
• Regulation: Changes from data protection rules under the Digital Personal Data Protection Act, sector regulators, consumer protection law and IT rules.

Industry Context: Where Tricog Fits

India's technology startup ecosystem is one of the largest in the world, supported by cheap data, a large base of smartphone users, digital public infrastructure and a deep engineering talent pool. Companies now build for education, software, mobility, logistics, agriculture, defence, media and more, selling both to Indian customers and abroad.

Durable technology companies usually combine a clear customer problem with repeatable distribution and disciplined unit economics. Growth funded only by spending tends to fade, while products that customers keep using and paying for build compounding advantages.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Tricog

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Tricog.

Bull case

• A large and growing base of digital users and businesses expands the addressable market.
• Recurring revenue and strong retention can compound growth.
• Selling into global markets widens the opportunity beyond India.

Bear case

• Heavy competition can compress pricing and margins.
• Dependence on external funding can force painful cost cuts.
• Regulation or platform changes can disrupt a product quickly.

Lessons Founders and Investors Can Take from Tricog

Studying a company in the Healthtech, cardiac AI space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Tricog.

• Solving a clear, frequent customer problem matters more than adding features.
• Retention and repeat usage are better health signals than sign-ups.
• Disciplined spending extends runway and keeps options open when funding tightens.
• Distribution, not just product quality, decides who wins in crowded markets.
• Building trust through data protection and reliability is part of the product.

How to Evaluate Tricog as a Startup

• Customer clarity: Can Tricog name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Tricog is part of India’s growing Healthtech, cardiac AI ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. Public sources can also describe the same company in different ways, so it is worth checking dates, definitions and whether a figure refers to revenue, total income or transaction value, and whether it covers one entity or a wider group, before drawing conclusions. Small differences in rounding, currency conversion or reporting periods can also change how a figure reads. Comparing the same figure across several recent reports helps show whether it is stable or has changed over time. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Tricog FAQs: Frequently Asked Questions

What is Tricog?

Tricog Health is a Bengaluru-based Indian healthtech company that combines AI with in-house cardiologists to read ECGs and other cardiac tests remotely for hospitals and clinics. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Tricog?

Tricog was founded by Charit Bhograj, Zainul Charbiwala, Udayan Dasgupta, and the company reports a founding year of 2015.

How much funding has Tricog raised?

About $30 million per company statement in 2023 (aggregators range from about $21 million to $32.5 million). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Tricog make money?

Tricog earns revenue from its Healthtech, cardiac AI products and services sold to businesses, institutions, consumers, learners and public-sector buyers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Tricog?

Reported rivals include Qure.ai, Agatsa, Cardiologs, Ultromics. See the competitor comparison above for how they differ.

What are the main risks for Tricog?

Main risks include competition: low barriers to entry and well-funded rivals can compress pricing and slow growth, funding and capital needs, competition and regulation by data protection rules under the Digital Personal Data Protection Act, sector regulators, consumer protection law and IT rules. This is educational content, not investment advice.

Related Startup Deep Dives: PharmEasy — PharmEasy: Rs 5,664 Cr revenue, Rs 2,533 Cr loss in FY24 | Credilio — Credilio: Mumbai fintech selling credit via agents. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.